Formulary guidance and transparency from P&T to point of care


Reality Check on Epilepsy

Market access for epilepsy treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 39% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In June 2020, the FDA approved Zogenix, Inc.'s Fintepla (fenfluramine) to treat seizures associated with Dravet syndrome in people at least 2 years old. The price for a 30 mL bottle is $1,278
  • Key Findings: Antiepileptic drugs (AED) are one of the protected Medicare classes, so management of brand-name products is restrictive but less so than in other classes. AEDs are also included in some state carve-out plans, such as Michigan's

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.